What are the available and emerging therapies for Carbapenem-resistant Enterobacterales?
Carbapenem-resistant Enterobacterales (CRE) are critical-priority pathogens with limited treatment options and high mortality rates 1. Doctors must choose from traditional antibiotics, newer agents, or combination therapies depending on the specific resistance pattern of the infection 14. Beyond standard drugs, emerging strategies like fecal microbiota transplantation (FMT) and selective digestive decontamination (SDD) are being used to help clear these bacteria from the body 3.
What the research says
Future priorities include conducting high-quality randomized controlled trials to optimize treatment strategies 1. Integrating rapid molecular diagnostics into routine practice is essential to facilitate precision therapy 1. Additionally, developing novel agents and synergistic combination approaches is necessary to address the ongoing spread of CRE 1.
What to ask your doctor
- Which specific antibiotic or combination therapy is recommended for my CRE infection based on my susceptibility test results?
- Are there emerging treatments like cefiderocol or ceftazidime-avibactam that might be appropriate for my case?
- Could fecal microbiota transplantation or selective digestive decontamination help clear the bacteria in my gut?
- What are the risks and benefits of using traditional antibiotics like polymyxins versus newer agents?
- How can rapid molecular diagnostics help tailor my treatment plan more effectively?
This question is drawn from common patient questions about Infectious Disease and answered using cited medical research. We do not provide individualized advice.